Moderna is up 20% YTD, with a golden cross suggesting a trend reversal. Momentum indicators make it a top 2026 pick.

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 ...

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

Moderna MRNA shares soared 10.9% in the last trading session to close at $35.66. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey ...

Stéphane Bancel, CEO of vaccine maker Moderna, addressed shareholders in a letter that dissected the events of 2025 while ...

In the latest trading session, Moderna (MRNA) closed at $33.86, marking a -5.66% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%. Meanwhile, the Dow ...

This stock is a great choice for cautious and aggressive investors.

The complaint alleges that Moderna used the patented fluorescent protein technology without permission during preclinical ...

Forbes contributors publish independent expert analyses and insights. Jack is a career business journalist an an award-winning podcast host. Speed-to-market has always been critical in the life ...